The ephemeral world of biotech valuations
Biotech valuations are ineffable: In the startup world, they’re often based on abstract information that’s kept close to the chest. That’s largely because until a drug is approved, investors aren’t even really thinking about concrete numbers or sales trends.
“Biotechs get valued based on promise,” as one attorney involved in startup fundraising told STAT.
STAT's Kate Sheridan takes a closer look at exactly how biotech valuations are calculated these days. Among the factors: the pedigree of a company's management team — and, obviously, the strength of its data.
STAT's Kate Sheridan takes a closer look at exactly how biotech valuations are calculated these days. Among the factors: the pedigree of a company's management team — and, obviously, the strength of its data.
.png)
No hay comentarios:
Publicar un comentario